SCHEMBL18929902

SCHEMBL18929902

COc1ncnc(OC)c1-c1ccc(Br)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EDNRB P24530 9/20 0.39
EDNRA P25101 9/20 0.39
IKBKB O14920 1/20 0.37
CHUK O15111 1/20 0.37
EGFR P00533 1/20 0.36
KDR P35968 1/20 0.36
HPGD P15428 2/20 0.36
RAB9A P51151 2/20 0.36
SLC6A2 P23975 1/20 0.36
TSPO P30536 1/20 0.36
DRD3 P35462 1/20 0.36
LMNA P02545 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
ATM Q13315 1/20 0.35
ADK P55263 1/20 0.35
PDPK1 O15530 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4836631 0.78 AURKA (0.47) HPGDRAB9ALMNAMEN1KMT2A
SCHEMBL21180006 0.77 MCL1 (0.41) EDNRBEDNRAHPGDRAB9ANPSR1
SCHEMBL2037410 0.76 PDPK1 (0.35) KDRHPGDRAB9AMEN1KMT2A
SCHEMBL23042145 0.74 LTA4H (0.52) EGFRKDRHPGDRAB9AMEN1
SCHEMBL2036379 0.74 RXRA (0.49) KDRRAB9ANPC1ALDH1A1TSHR
SCHEMBL9891389 0.74 IKBKB (0.46) IKBKBCHUKKDRRAB9ALMNA
SCHEMBL15333930 0.72 KDR (0.46) KDRHPGDRAB9AMEN1KMT2A
SCHEMBL17003300 0.72 ALDH1A1 (0.40) EDNRBEDNRAIKBKBCHUKKDR
SCHEMBL4536423 0.71 PDPK1 (0.43) EGFRKDRHPGDRAB9ALMNA
SCHEMBL1001064 0.68 ALOX15 (0.40) IKBKBCHUKKDRRAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368104-A1 Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same DONG WHA PHARM. CO., LTD. (KR) 2024-11-07 US disclosed
WO-2022208382-A1 NOVEL DIALKOXYNAPHTHO[2,3-C]FURAN-1(3H)-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESPIRATORY DISEASE OR SARS-COV-2 INFECTION DISEASE, COMPRISING SAME 동화약품주식회사 2022-10-06 WO disclosed
WO-2017093903-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF MACITENTAN LAURUS LABS PRIVATE LIMITED (IN) 2017-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368104-A1 Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same IL5, ACE2, IL15 EDNRB 3077/4885EDNRA 2391/4885IKBKB 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.